ArticleOncotarget2017

miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression.

Michael R Epis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.